6^th Annual Dementia Congress

Disease-Modifying Therapies & Drug Development

Developing effective therapies that can modify the progression of dementia is a central goal in neurology and neuroscience. This topic will provide a comprehensive overview of current and emerging pharmacological interventions designed to slow or halt disease progression rather than only addressing symptoms. Discussions will cover mechanisms of action, including targeting amyloid-beta accumulation, tau pathology, neuroinflammation, and synaptic dysfunction. Participants will examine preclinical and clinical trial data, highlighting successes, limitations, and lessons learned from past and ongoing studies. The session will also explore innovative approaches such as gene therapy, immunotherapy, and small molecule drugs that aim to correct underlying molecular and cellular abnormalities. Attention will be given to challenges in translating laboratory findings into clinical applications, including issues related to drug delivery, safety, efficacy, and patient selection. Collaborative strategies between academic institutions, pharmaceutical companies, and regulatory agencies will be emphasized to accelerate therapeutic development. Attendees will gain insights into personalized treatment approaches and precision medicine strategies that target specific patient populations based on biomarkers, genetic profiles, and disease stage. This topic aims to equip researchers, clinicians, and industry professionals with the knowledge needed to contribute to the next generation of disease-modifying therapies and improve outcomes for individuals affected by dementia.